Chromoblastomycosis with 18 years of evolution
DOI:
https://doi.org/10.18203/2320-6012.ijrms20232442Keywords:
Chromoblastomycosis, Treatment, Differential diagnosisAbstract
Chronic infectious, granulomatous and suppurative dermatosis, classified among the subcutaneous mycoses, caused by species of pigmented dematiaceous fungi, more prevalent in tropical and subtropical regions and caused by the traumatic implantation of dematiaceous fungal species, where the presence of muriform bodies are an expression of the causal agent in the grafted tissue, characteristic of chromoblastomycosis considered the second implantation mycosis in the world, it manifests itself with slow and progressive growth lesions of exophytic and verrucous plaques and black dots on the surface. The disease is considered a neglected and occupational disease, which occurs mainly among agricultural workers, and coconut and babassu harvesters, lumberjacks and traders of agricultural products. It is important to highlight that people at risk of contracting chromoblastomycosis work in tropical countries, where the temperature can be above 40 °C in summer, and generally refuse to wear protective equipment during the day (shoes, gloves, and clothes), although they know that this type of prophylactic measure can prevent different types of diseases. These vulnerable people often live in low-income countries and sometimes live far from medical services and, once infected, do not seek medical attention. We report below an exuberant and unusual case of lower limb chromoblastomycosis with a history of 18 years of evolution. The diagnosis was established by direct mycological examination, culture and microculture that identified the agent of the Fonsecaea species, and histopathological examination.
References
Queiroz-Telles F. Chromoblastomycosis: A neglected tropical disease. Rev Inst Med Trop São Paulo. 2015;57:46-50.
Weedon D, van Deurse M, Allison S, Rosendahl C. Chromoblastomycosis in Australia: an historical perspective. Pathology. 2013;45:489-91.
Queiroz-Telles F, de Hoog S, Santos DW, Salgado CG, Vicente VA, Bonifaz A, et al. Chromoblastomycosis. Clin Microbiol Rev. 2017;30:233-76.
Rudolph M. Uber die brasilianisch “Figueira” (Vorlaufige Mitteilung). Arch Schiffs-und Tropen-Hyg. 1914;18:498-9.
Soto MCR, Malaga G. Subcutaneous mycoses in Peru: a systematic review and meta-analysis for the burden of disease. Int J Dermatol. 2017;10:1037-45.
Buot G, Bachmeyer C, Benazeraf C. Chromoblastomycosis: an unusual diagnosis in Europe. Acta Derm Venereol. 2005;85:259-60.
Queiroz-Telles F, Fahal AH, Falci DR. Neglected endemic mycoses. Lancet Infect Dis. 2017;17:367-77.
Agarwal R, Singh G, Ghosh A. Chromoblastomycosis in India: review of 169 cases. PLoS Negl Trop Dis. 2017;11:1-13.
Pindycka-Piaszczyńska M, Krzyściak P, Piaszczyński M, Cieślik S, Januszewski K, Izdebska-Straszak G, et al. Chromoblastomycosis as an endemic disease in temperate Europe: first confirmed case and review of the literature. Eur J Clin Microbiol Infect Dis. 2014;33(3):391-8.
Álvarez-Montiel I, Bonifaz AA. Cromoblastomicosis en placa superficial. Manifestación de una variante poco habitual. Dermatol Ver Mex. 2014;58:529-33.
Ramírez O. Cromoblastomicosis en El Salvador. Arch Col Med El Salv. 1956;9:218-23.
Torres-Guerrero E, Isa-Isa R, Isa M, Arenas R. Chromoblastomycosis. Clin Dermatol. 2012;30:403-8.
Cueva AJ. Cromoblastomicosis en Honduras. Rev Med Hondur. 1956;24:112-21.
Foster HM, Harris TJ. Malignant change (squamous carcinoma) in chronic chromoblastomycosis. Aust N Z J Surg. 1987;57:775-7.
Belda Jr. W, Criado PR, Casteleti P, Passero LFD. Chromoblastomycosis evolving to sarcomatoid squamous cell carcinoma: a case report. Dermatol Rep. 2021;13:2.
Martinez RL,Tovar LJM .Cromoblastomycosis. Clin Dermatol. 2007;25:188-94.
Pavlidakey GP, Snow SN, Mohs FE. Chromoblastomycosis treated by Mohs micrographic surgery. J Dermatol Surg Oncol. 1986;12:1073-5.
Castro LGM, Pimentel RR, Lacaz CS. Treatment of chromomycosis by cryosurgery with liquid nitrogen: 15 tear’s experience. Int J Dermatol. 2003;42:408-12.
Tsianakas A, Pappai D, Basoglu Y, Metze D, Tietz HJ, Luger TA, et al. Chromomycosis successful CO2 laser vaporization. J Eur Acad Dermatol Venereol. 2008;22:1385-6.
Lyon JP, Moreira LM, Carvalho VS. In vitro photodynamic therapy against Fonsecaea pedrosoi and Cladophialophora carrionii. Mycosis. 2013;56:157-61.
Bolzinger T, Pradinaud R, Saint-Marie D. Traitment de quatre cas de chromomycose à Fonsecaea pedrosoi par l’association 5-fluorocytosine-itraconazole. Nouv Dermatol. 1991;10:462-6.
Gupta AK, Taborda PR, Sanzovo AD. Alternative week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529-34.
Azevedo CDM, Marques SG, Resende MA, Gonçalves AG, Santos DV, da Silva RR, et al. The use of glucan as immunostimulant in the treatment of a severe case of chromoblastomycosis. Mycoses. 2008;51:341-4.
Texeira de Sousa MG, Belda Jr W, Spina R, Lota PR, Valente NS, Brown GD, et al. Topical application of imiquimod as a treatment for chromoblastomycosis. Clin Infect Dis. 2014;58:1734-7.
Belda Jr W, Criado PR, Passero LFD. Successful treatment of chromoblastomycosis caused by Fonsecaea pedrosoi using imiquimod. J Dermatol. 2020;1-4.
Belda Jr W, Criado PR, Passero LFD. Treatment of chromoblastomycosis with combinations including acitretin: a report of two cases. Am J Trop Med Hyg. 2020;103:1852-4.